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INTRODUCTION 
 
     Carcinoma Oesophagus is the 6th most common cancer worldwide which 
represents 4% of all newly diagnosed cancers.  It is generally considered as an 
extremely aggressive tumor with poor prognosis with an overall survival  rate of 
5%.  Despite great advances in surgery, critical care, radiotherapy, chemotherapy, 
esophageal cancer afflicts a large number of patients every year and almost 
matching that number is the expected cause of death. 
 
     They remain as a major therapeutic problem confronting the surgeon.  They are 
likely to result in early mortality owing to the likelihood of advanced disease at the 
time of diagnosis and the challenging nature of treatment. 
 
     Traditionally, esophageal cancer has been squamous type in patients with usual 
risk factors for other aerodigestive tract carcinomas, specifically, smoking ( 5 fold) 
and alcohol ( 5 fold) abuse.  Heavy smoking and heavy drinking combine to 
increase the risk 25 to 100 fold.  Remarkably within North America and Europe, 
the incidence of adenocarcinoma rose 100% in the 1990s. 
 
              Although the origin of this shift remains unknown, carcinoma of the 
esophagus now appears to affect younger, healthier patients.  Nutritional factors 
and potential carcinogens have been incriminated, and familial disease Tylosis, 
which is an inherited autosomal dominant trait,also predisposes to esophageal 
carcinoma.  Some esophageal lesions are premalignant, including Barretts 
esophagus, Plummer Vinson syndrome, Achalasia, etc., 
 
     In recent years, with an improved standard of surgical technique and 
perioperative & postoperative care, substantial reduction of operative morbidity & 
mortality has been achieved. 
 
     The study of esophageal cancer is interesting because of its biologic behaviour; 
it infiltrates locally,involves adjacent lymph nodes, and metastasizes widely by 
hematogenous spread.   
 
     The prognosis form patients with invasive squamous cell carcinoma is poor;  
the overall 5-year survival rate for patients with treated tumors is 5 to 12% 
 
 
                                       
 
 
 
 
HISTORICAL REVIEW 
 
     An esophageal growth causing swallowing difficulty was first described in 
Western literature by Galen in 2nd century, which was documented as a cause for 
dysphagia by Avicenna in 10th century.  Surgery for Carcinoma esophagus began 
in 1877, when Czerny carried out the first successful resection of cervical 
anastomosis.  However, not until 1913 was the first successful resection of a 
thoracic Carcinoma esophagus performed. 
 
     The first successful one stage resection of a thoracic Carcinoma esophagus & 
reconstruction, using the whole stomach was described by Obsawa in 1933.  
Transabdominal or Trans thoracic esophagectomy with immediate esophago 
gastrostomy was done in 1946.  In 1978 Orringer, revived the technique of Trans 
hiatal esophagectomy without thoracotomy.  Multi-modal therapeutic approach 
such as adjuvant and neo-adjuvant chemoradiation for the treatment of esophageal 
cancers was introduced in the year 1984. 
 
     Newer techniques & treatment strategies are being planned since then and an 
effective tumoricidal regimen is quite a possibility in the near future.     
 
 
                                                  AIM OF THE STUDY 
 
The objectives of this prospective clinical study are: 
1) To know the incidence of Carcinoma esophagus with regard to age, 
socioeconomic status in our region. 
 
2) To know the aetiological & epidemiological  factors associated with these 
Carcinoma. 
 
3) To study the common histological types of Carcinoma esophagus. 
 
4) To know the clinical features & possible investigations to aid the diagnosis 
& resectability of these tumors. 
 
5) To evaluate the role Trans Hiatal oesophagectomy in Carcinoma 
oesophagus & its outcome. 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
ANATOMY OF THE ESOPHAGUS 
 EMBROLOGY: 
     Oesophagus starts to develop in the 4th week of embryonic development, from 
the Foregut, immediately caudal to the primordial pharynx & extends to the 
fusiform dilatation in the foregut.  It elongates rapidly due to growth & descent of 
heart & lungs reaching its final length by 7th week. 
 
     By 5th week of development, the oesophagial epithelium is columnar & 2 cells 
thick and cilia develop by 10th week.  The epithelial lining proliferates & partly or 
completely obliterates the lumen by 8th week, which is replaced with stratified 
squamous epithelium by 4th month.  The inner circular layer is recognizable by 5th 
week & outer longitudinal layer takes shape by 8th week.  Oesophagus attains its 
final length at 7th week of gestation, whose length at birth is 8 – 10 cm. 
 
 
 
 
 
TOPOGRAPHY: 
     Oesophagus is a hollow muscular tube of about 25cms long which connects 
pharynx to the stomach.  It commences in the neck, level with the lower border of 
cricoid cartilage ( C6 vertebra) and descends mainly anterior to the vertebral 
column traversing the diaphragm at the level of T10, ending in the abdomen at the 
cardia orifice of stomach at the level of T11. 
 
     Topographically, the esophagus is generally vertical, but has two shallow 
curves.  Immediately below the pharynx, it is a midline structure, but inclines to 
the left as far as the root of neck, gradually returning to the midline near T5 
vertebra & deviates to the left again at T7.  It also curves in a coronal plane to 
follow the cervical & thoracic curvatures of vertebral column.  The surgical 
relevance of this is that the cervical esophagus is best approached from the left 
side of neck & thoracic portion through right side of thorax, except the lower third.  
It lies anterior to vertebral column & longus colli muscles, posterior to trachea & 
adjacent to descending aorta. 
 
     There are a number of naturally occurring anatomical narrowings in the 
oesophagus.  The cervical constriction occurs at the level of cricopharynx at 
approximately 15 cm from the incisors.  The next constriction is at where it is 
crossed by aortic arch at 22 cm & by left main bronchus at 27 cm. The another 
constriction is at the level where it passes through diaphragmatic hiatus at the 
cardio-oesophageal junction at 37 – 40 cm from the incisors. 
The esophagus is arbitrarily divided into 3 segments: 
     The cervical portion of esophagus is approximately 5 cm long & descends 
between vertebral column, from level of C 6 to the level of interspace between 1st 
and 2nd thoracic vertebrae posteriorly.  The recurrent laryngeal lies in the right & 
left grooves between trachea and esophagus.  The left recurrent laryngeal nerve 
lies close to esophagus than the right. 
 
     The Thoracic esophagus is 20 cm  long and 2.5 cm diameter, which runs in the 
superior mediastinum between trachea & vertebral column, passing behind and to 
the right of aortic arch to descend in the posterior mediastinum along the right side 
of the descending thoracic aorta.  It then deviates further to the left & anteriorly 
entering the diaphragmatic hiatus at the level of T 10.  On either side it is bounded 
by parietal pleurae. 
 
     Clinically, it is divided into 3 parts.  The upper thoracic esophagus extends 
from cricopharyngeus to the carina.  The middle thoracic esophagus extends from 
carina to halfway between carina & the OG junction.  The lower thoracic one 
exists from halfway between carina & OG junction to include lower 3rd esophagus. 
 
     Oncologically, it is divided into Supra carinal ( Upper esophagus ) & Infra 
carinal ( middle & lower oesophagus ). 
     Abdominal oesophagus ( 2cm ) emerges from the right diaphragmatic crus 
slightly to left of midline at the level of T10 & it is surrounded by Phreno 
oesophageal membrane.It is covered by peritoneum on its front and left side.  
Behind it is the left crus of diaphragm.  It includes a portion of Lower esophageal 
sphincter (LES), which is the portion of esophagus subjected to positive pressure 
environment of esophagus. 
 HISTOLOGICAL STRUCTURE: 
     The esophagus is mucosal lined muscular tube lacking the serosa.  It consists of  
four layers. 
1. The fibrous adventitial layer, which is irregular and consists of loose 
areolar connective tissue containing elastin fibres, which permit 
considerable movement during swallowing. 
 
2. Muscular layer,  composed of outer thicker longitudinal & inner circular 
layer.  The longitudinal fibres originate from a cricoesophageal tendon 
arising from the dorsal upper edge of anteriorly located cricoid cartilage. 
The longitudinal fibres surround the whole length of esophagus with a 
continous coat except posterosuperiorly where the longitudinal fibres 
separate and sweep around to the anterior aspect of esophagus before their 
insertion into posterior aspect of cricoid.  This configuration allows a “V” 
shaped area in the posterior wall covered by cricopharynx above & circular 
fibres below. 
The circular layer is thicker than outer longitudinal layer.  The geometry of 
circular muscle is helical and makes the peristalsis to assume a worm like 
drive. 
 
3. the submucosal layer, which is very loose in order to permit the dilatation 
of esophagus during swallowing.  It loosely connects mucosal & muscular 
layers & contains large blood vessels, nerves, mucous glands. 
 
4. The mucosal layer, made of non-keratinising squamous epithelium which 
is arranged in longitudinal folds especially at lower end.  The mucosal layer 
consists of lining epithelium, connective tissue with papilli  ( lamina 
propria) and nonstriated muscularis mucosa. 
  
 
 
 
 
 
 
VASCULATURE 
ARTERIAL SUPPLY 
 
     The esophagus is nourished by numerous segmental arteries all of which 
contribute to the extensive capillary network. 
     The cervical esophagus receives blood from Superior Thyroid artery as well as 
Inferior Thyroid Artery of Thyrocervical trunk with both sides communicationg 
through collateral vessels. 
     The Thoracic esophagus receives blood supply from Bronchial arteries, 4 to 6 
aortic oesophageal arteries, supplemented by collateral vessels from Inferior 
Thyroid Artery, Intercostal Arteries, Inferior phrenic arteries and left gastric 
artery. 
 
     The abdominal oesophagus receives its supply from the ascending branch of 
left gastric artery and Inferior phrenic artery.  On entering the wall of oesophagus, 
the arteries assume a “T”- shaped division to form a longitudinal plexus of 
capillary network in the submucosa. 
 
 
 
 
 
VENOUS DRAINAGE 
     Blood from capillaries of oesophagus flows into a submucosal venous plexus & 
then into a peri oesophageal venous plexus from which the oesohageal vein 
originate. 
     In the cervical region, the oesophageal veins empty into Inferior Thyroid Vein, 
in the thoracic region empty into bronchial, azygos, hemi azygos veins and in the 
abdominal region empty into coronary veins.   
 
LYMPHATIC DRAINAGE 
     The lymphatics form extensive mucosal, submucosal, muscularis and 
adventitial plexuses which communicate freely.  These are grouped into three 
main tiers: 
Ist tier :   It composed of lymph nodes along the side of oesophagus     
                      ( para esophageal )   
IInd tier:  It composed of the intermediate group, which contains mainly the   
                  mediastinal lymph nodes. 
IIIrd tier: It composed of deep cervical, supraclavicular, tracheobronchial and 
celiac  
                    nodes from above downwards. 
     In general, lymph drainage from the upper 2\3 rds of oesophagus proceeds in 
cephalic direction and in lower 1\3 rds proceed in caudal direction to 
subdiahragmatic and celiac nodes. 
     Lymph drainage of Gastro esophageal junction mainly follows the arteries 
supplying it. 
 
     The Thoracic duct forms from the continuation of Cisterna chyli at a level 
between T12 and L2 and to the right side of abdominal aorta.  It enters the 
posterior mediastinum through aortic hiatus at the level of T10 to T12.  It 
continues cephalad on the anterior surface of vertebral column between aorta and 
Azygos vein behind oesophagus. 
 
     At T4 level, the duct crosses to the left, passes under aortic arch and continues 
along the left side of oesophagus, to ascend into the neck posterior to left 
subclavian artery. 
 
     In the neck, the duct lies anterior to the vertebral vessels, Thyrocervical trunk, 
Phrenic Nerve and it enters the venous system at the junction of left subclavian 
and left Internal Jugular Vein. 
 
     The rich mucosal and submucosal networks allow tumor to extend 
intramurally.  In addition, there is shared lymphatic drainage of the trachea and 
esophagus, thus making en bloc esophagectomy impossible for lesions above the 
tracheal bifurcation. 
 
 
 
 
NERVE SUPPLY 
     Two plexuses of nerves in oesophageal wall ( Meissner’s & Auerbach’s 
plexuses) form networks of multipolar ganglion, the processes of which are in 
contact with one another.  Postganglionic fibres of these plexuses innervate the 
smooth muscle cells. 
     The esophagus has both sympathetic and parasympathetic innervation. The 
recurrent laryngeal nerve branches of the vagus provide parasympathetic 
innervation to the cervical esophagus as well as innervation to the upper 
esophageal sphincter.  
 
      Sympathetic innervation consists of fibers to the cervical esophagus from the 
superior and inferior cervical sympathetic ganglia, to the thoracic esophagus from 
the upper thoracic and splanchnic nerves, and to the intra-abdominal esophagus 
from the celiac ganglion. 
 
PHYSIOLOGY 
     Swallowing is a complex, rapid series of events that has been divided 
radiologically into six phases.  Three types of contractions are seen in the 
esophageal body.  Primary peristalsis is progressive and is triggered by voluntary 
swallowing.  Secondary peristalsis is also progressive, but it is generated by 
distension or irritation, not by voluntary swallowing. 
       Tertiaty contractions are non-progressive simultaneous contractions that 
may occur either after voluntary swallowing or spontaneously between swallows. 
 
EPIDEMIOLOGY 
     Carcinoma esophagus has the greatest variation in geographic distribution.  The 
incidence is western countries is low.  In U.S. the yearly incidence is 6.0 \ 
1,00,000 population for males & 1.6 \ 1,00,000 in females. 
     In the West, it is predominantly a disease of elderly males with an overall 
incidence of 10 – 20 per hundred thousand population per annum.  The highest 
incidence is in France followed by Scotland where the frequency of disease has 
more than doubled in the past 30 years.  It is 20 – 30 times more common in 
China, Iran, and the Transki region of South Africa than West. 
 
     Through out the world, the incidence is increasing in both sexes with increasing 
trend towards females.  There is a declining trend in Finland. 
 
     The incidence of Squamous cell carcinoma is increasing in Blacks than in 
whites.  Adenocarcinoma, once an unusual carcinoma is diagnosed with increasing 
frequency & now it accounts for more than 50% in western countries.  It is more 
common in whites than blacks. 
 
 
 
 
  
ETIOLOGY 
DIETARY 
     Pickled vegetables, preserved meat, salted dry fish ( rich in Nitrosamines) 
     Micro nutrient deficiency ( Vitamin A, B12, C, E, Beta – Carotene) 
     Trace element deficiency ( Co, Cu, Mo, Zi) 
 
ACQUIRED 
     Tobacco chewing  
     Smoking 
     Alcoholism 
     Chronic oesophagitis 
     Achalasia Cardia 
     Barrett’s Oesophagus 
     Corrosive strictures 
     Plummer Vinson Syndrome 
     Other Aero - digestive malignancy 
 
HEREDITARY 
     Tylosis      
 
 
DIETARY FACTORS 
     World wide, nutritional deficiencies have been implicated in the pathogenesis.  
Because nitrates and nitrites can be converted within the body to carcinogenic   N 
– Nitrosamines, they can cause malignancy. 
      The apparent risk reduction brought about by citrus fruits may be due to 
inhibition of endogenous nitrosamination by Vitamin C.  The high prevalence of 
esophageal cancer in Gassim region in Saudi Arabia, has been linked to 
contamination of water by impurities such as petroleum oils. 
 
ACQUIRED FACTORS 
 
     The risks associated with tobacco use appear to increase with the number of 
cigarettes smoked per day, duration of smoking and tar content.    Alcoholism act 
both as an carcinogen & a promoter. 
 
     Endoscopic surveys in Iran & China showed that chronic esophagitis  is 
directly to esophageal cancer in 65% to 80%. 
 
     In patients with Achalasia, the prevalence of malignancy is 3 to 6%.   It has 
been estimated that the incidence of esophageal cancer among patients with a 
history of caustic ingestion is 1000 fold greater. 
HEREDITARY FACTORS 
     Tylosis, an autosomal dominant disorder, characterized by hyperkeratosis of 
skin of palms & soles. They are more prone to develop Squamous cell carcinomas, 
more common in 6th to 7th decade.  ` 
 
PATHOLOGY 
SQUAMOUS CELL CARCINOMA 
     Squamous cell carcinoma accounts for about 90% if esophageal carcinoma.  It 
arises from esophageal mucosa and histologically it is characterized by invasive 
sheets of cells that run together and are  polygonal, oval or spindle shaped with a 
distinct or ragged stromal epithelial interface. 
 
     They are mainly located in Thoracic oesophagus, approximately 60% of these 
tumors are found in the middle 3rd and about 30% in distal 3rd. 
     The four major gross pathologic presentations are: 
1) Fungating type. 
2) Ulcerative variety. 
3) Infiltrative variety. 
4) Polypoidal growths. 
 
 
ADENOCARCINOMA 
     It usually originates from the Barett’s oesophagus following longstanding 
GastroEsophageal Reflux  and it is the most common type in U.S. It arises from 
superficial & deep glands of esophagus mainly in lower 3 rd oesophagus, 
especially near OG junction. 
It may have one of three origins; 
1) Oesophageal submucosal glands. 
2) Heterotopic islands of columnar epithelium. 
3) Malignant degeneration of metaplastic epithelium (Barrett’s oesophagus) 
     Unlike the mucin secreting cells of origin, Adenocarcinoma has a reduced 
cytoplasmic nuclear ratio. 
 
CLASSIFICATION OF OG JUNCTON TUMORS 
TYPE  I  : Adenocarcinoma of distal oesophagus,arising from metaplastic                               
epithelium, infiltrating the OG junction. 
TYPE II :   Carcinoma of true cardia , arising from cardia epithelium or short  
segments with intestinal metaplasia at OG Junction. 
TYPE III:   Subcardial carcinomas infiltrating the OG Junction. 
 
     The incidence of adenocarcinoma has been rising steadily. Prospective 
evaluation has suggested that incidence of adenocarcinoma in patients with 
Barrett’s esophagus is 40 to 125 times that expected in the general population. 
 
     In addition to classic Barrett’s esophagus, there is a concern that patients with 
short segment Barrett’s may also be at risk.  In combined data from the Cleveland 
clinic and the University of Arizona, it was suggested that the risk for 
adenocarcinoma was the same. 
 
OTHER MALIGNANT TUMORS 
 ADENOID CYSTIC CARCINOMA 
     The prevalence of this tumor is approximately 1 in 10,000 esophageal tumors.  
It occurs most commonly in elderly men and its presentation and site preference 
are similar to those of squamous cell carcinoma.  Distant metastasis dominate the 
clinical course and the prognosis is poor. 
 
 
 
 
 
SARCOMAS 
    Sarcomas of esophagus accounts for 0.8% of all oesophageal tumors.  
Epidermoid carcinoma with spindle cell features is the more common variety and 
includes carcinosarcoma and pseudosarcoma.  Both the carcinomatous and 
sarcomatous elements of carcinosarcoma may metastasize, whereas usually only 
the carcinomatous elements of pseudosarcomas metastasize. 
 
     Another type of esophageal sarcoma is true sarcoma arising from mesenchymal 
tissue.  This group includes leiomyosarcomas, rhabdomyosarcomas and 
fibrosarcomas. 
 
     Kaposi’s sarcoma of the esophagus is increasingly seen with the emergence of 
the acquired immunodeficiency syndrome. 
 
LYMPHOMA 
     Despite its rarity, accurate diagnosis of primary esophageal lymphoma is 
important because it is potentially curable.  In most patients, esophageal 
involvement by lymphoma is secondary.  About ten cases of isolated primary 
esophageal lymphoma has been published.  The advent of AIDS has brought about 
an increase in the frequency of primary esophageal lymphoma.  The lesions may 
be seen as a mass or as an ulcer which can be indistinguishable from an infectious 
ulcer. 
 
ENDOCRINE CELL TUMORS ( APUD OMAS): 
     Apudomas are rare in the esophagus ( 0.8% to 2.4% of malignant esophageal 
neoplasm).  Primary small cell carcinoma is the most common variety. 
 
PRIMARY MALIGNANT MELANOMA 
     Primary malignant melanoma, an extremely rare tumor, occurs primarily in 
older persons of either sex, accounting for only 0.1% of primary esophageal 
cancer.  Tumor behavior is similar to melanomas elsewhere in the body; most 
patients die from distant metastases and the 5 year survival rate is about 4%. 
 
ADENOSQUAMOUS CARCINOMA 
     It is a rare tumor that exhibits infiltrating elements of both adenocarcinoma and 
squamous carcinoma; however, these elements are not intimately mixed.  When 
mature squamous epithelium is present, it is termed as Adenoacanthoma. 
 
     Other uncommon esophageal malignancies include mucoepidermoid 
carcinoma, primary esophageal carcinoid tumor and metastatic esophageal tumors 
from the breast, lungs and malignant melanoma from else where. 
 
 
 
 
MODE OF SPREAD 
     Carcinoma esophagus is notorious for its aggressive biological behaviour.  It 
infiltrates locally, involves adjacent lymph nodes and metastasizes widely by 
hematogenous spread. Lack of an esophageal serosal layer favours local tumor 
extension. 
 
     Tumors of upper & middle 3rd, infiltrate the tracheobronchial tree, aorta, Left 
Recurrent Laryngeal nerve, whereas lower 3rd tumor may invade diaphragm, 
pericardium, stomach. Cervical esophagus tend to drain to deep cervical, para 
oesophageal, posterior mediastinal nodes. 
 
CLINICAL FEATURES 
     In more than 85% of patients, the presenting symptom is dysphagia which, 
initially is for solids and later progresses to liquids as the obstruction becomes 
complete. 
 
     The second most common presenting complaint is recent weight loss in about 
40% of patients, owing to the combined catabolic & obstructive effects of tumor. 
 
     Chest pain is frequently reported as it arises from oesophageal spasms above a 
partially obstructing tumor, from irritation of esophagus by malignant ulceration 
or from direct invasion of mediastinal structures including spinal column. 
     Extension of tumor into tracheobronchial tree can cause stridor & if a 
tracheoEsophageal fistula develops, coughing, choking, and Aspiration 
pneumonia results.  Rarely severe bleeding from erosion into the aorta or 
pulmonary vessels occur. 
 
     Vocal cord paralysis is caused by invasion of left Recurrent laryngeal nerve 
by primary tumor or by lymphatic secondaries.  Systemic organ secondaries 
manifests as jaundice or bone pain.  Haemetemesis, regurgitation, Anorexia is 
the other symptoms that can suggest the disease. 
                
STAGING 
     Staging of the tumor is the critical step in determining which therapeutic option 
is appropriate.  The stage of a tumor is classified most frequently by the staging 
system devised by the American Joint Committee on Cancer.  This system is a 
TNM based system.  The ‘T’ (tumor) indicates the progressive degree (1 to 4) of 
invasion of the tumor into the esophageal wall.  ‘N’ stands for nodal involvement 
and ‘M’ for distant metastasis. 
 
     Prognosis and outcomes are determined by stage.  Five-year survivals for 
esophageal cancer are as follows:  Stage I, 50 to 55%; Stage II, 15 to 30%; 
Stage III, 6 to 17%; and Stage IV less than 5%. 
 
LYMPH NODES ( N STAGE ) 
     Lymph node involvement may be assessed by Endoscopic Ultrasound, CT, 
Positron Emission Tomography (PET), or Video Assisted Thoracoscopy and 
Laparoscopy. 
 
T – PRIMARY TUMOR 
     TO          No evidence of a primary tumor 
     Tis          Carcinoma in situ ( High grade dysplasia) 
     T1      Tumor invading the lamina propria, muscularis mucosae, or           
submucosa but not breaching the boundary between submucosa and  
muscularis propria.  
     T2       Tumor invading muscularis propria but not breaching the boundary  
between muscularis propria and periesophageal tissue. 
     T3          Tumor invading periesophageal tissue but not adjacent structures. 
      T4          Tumor invading adjacent structures. 
 
N – REGIONAL LYMPH NODES 
       N0         No regional lymph node metastasis 
       N1         Regional lymph node metastasis 
 
 
 
M – DISTANT METASTASIS 
       M0        No distant metastasis. 
       M1        Presence of distant metastasis  
 
STAGE GROUPING OF ESOPHAGEAL CANCER 
Stage  0         T0 N0 M0 
                      Tis N0 M0 
Stage  I         T1 N0 M0 
Stage  II       II A    T2 N0 M0 
                        T3 N0 M0   
                      II B    T1 N1 M0 
                                 T2 N1 M0 
Stage III                   T3 N1 M0 
                                  T4 Any N M0 
Stage IV                  Any T Any N M1 
 
DISTANT METASTASIS ( M STAGE) 
     Endoscopic Ultrasound is especially suited to visualize lymph nodes around the 
celiac axis and the left liver lobe ( both considered distant metastases).  CT is 
specific for liver, lung, and pleural metastases larger than 2cm in diameter, but 
evaluation with Fine Needle Aspiration or transbronchial biopsy is necessary for 
the determination of malignancy.  Bronchoscopy is required for patients with 
tumors of the upper &middle third of the esophagus to view the pharynx, larynx 
and tracheobronchial tree for synchronous and metachronous malignancies. 
 
CURRENT STAGING CLASSIFICATIONS 
     Based upon survival analysis indicating tumor penetration and lymph node 
metastases as the major prognostic factors, the WNM ( wall penetration, node and 
distant metastases ) system for staging was developed by skinner et al.  Tumors 
limited to above the muscularis mucosa would be equivalent to W0 designation,  
T1 and T2 tumors would equate to W1 classification, and T3 and T4 tumors to the 
W2 classification.  Ellis et al, compared the 1988 staging criteria with their 
modified Skinner WNM staging system and showed evidence that a modified 
staging system was more useful from a prognostic standpoint. 
     Stage 0             W0  N0  M0 
     Stage I              W0  N1  M0 
                               W2  N0  M0 
     Stage II            W1  N1  M0 
                               W2  N0  M0 
     Stage III           W2  N1  M0 
                               W1  N2  M0 
                               W0  N2  M0 
     Stage IV           Any W Any N M1 
 
 
INVESTIGATIONS 
1. X-RAY CHEST 
It is abnormal in only 50% of patients with findings such as an air fluid 
level in obstructed esophagus, a dilated esophagus, abnormal mediastinal 
soft tissue representing adenopathy or tracheal deviation.  The evidence of 
lung secondaries and pleural effusion can be noted. 
 
2. BARIUM SWALLOW  
A double-contrast, full column barium swallow is very useful; the 
sensitivity in detecting an esophageal carcinoma is between 74% and 97%.  
Reports indicate that it is less efficient in screening for patients with 
Adenocarcinoma developing from Barrett’s esophagus. 
     Fluoroscopically guided films taken at different angles are required in 
order to detect early lesions.  Usually, anteroposterior, lateral, left and right 
anterior oblique projections are necessary.  It can determine the location & 
length of tumor, and may reveal the presence of submucosal secondaries.  
The relationship of the tumor to the whole thoracic cavity and the tracheal 
bifurcation is useful in deciding the operative approach.  Deformity of the 
esophageal axis, such as tortuosity, angulation, deviation are signs 
indicating an advanced tumor with fixation and retraction from infiltration 
of the adjacent organs. 
ESOPHAGOSCOPY 
     It is usually performed on every patient who is being evaluated for the 
presence of an esophageal carcinoma.  The typical tumor is friable and 
exophytic,causing obstruction, or ulcerated with irregular raised borders.  
More subtle abnormalities include loss of esophageal wall motility caused 
by longitudinal submucosal infilltrlation.  Close inspection for second 
synchronous primary tumors should be performed, particularly in patients 
with Squamous cell carcinoma. 
 
     Measurement of the distance of the abnormalities from the incisors is 
valuable in planning therapy.  Important reference landmarks include 
cricopharyngeus, the aortic arch, the left mainstem bronchus, and the 
diaphragmatic hiatus.  When the endoscope can be passed through the 
tumor, measurement of the overall length of involvement is also useful.   
 
     Histologic documentation of  carcinoma is obtained routinely with cup 
forceps biopsies.  Even when performed carefully, however, such biopsies 
are nondiagnostic in more than 7% of cases, in which flexible fiberoptic 
endoscope is used.  The use of esophageal brush cytology can lead to a 
diagnosis of malignancy in some cases in which all biopsies are negative 
and serves as a valuable adjunct to the endoscopic techniques. 
 
3. ENDOSCOPIC ULTRASONOGRAM 
The anatomy of esophageal wall and the surrounding lymph nodes is 
assessed using this EUS.     Five distinct wall layers are identified in the 
normal esophagus, corresponding to the mucosa, submucosa, lamina 
propria, muscularis propria, and adventitia.  Esophageal cancer appears as 
an irregularly delineated hypoechoic mass on EUS.  The accuracy is 
greatest in patients with transmural tumors, particularly those involving 
adjacent structures.  The overall accuracy is 70% to 85%.  
 
     It is very much useful in detecting mediastinal lymph nodes for 
metastatic involvement.  Lymph nodes as small as 3 to 5 mm in diameter 
can be recognized.  However, qualitative criteria are more important in 
recognizing involved nodes, which are better circumscribed and have a 
more irregular hypoechoic internal pattern than that found in normal lymph 
nodes.   EUS guided FNAC can assess Lymph nodes in perioesophageal, 
periaortic, subcarinal, Coeliac axis regions. 
 
4. BRONCHOSCOPY 
Bronchoscopic examination is mandatory in patients with esophageal 
carcinoma involving regions adjacent to the trachea or mainstem bronchi.  
The airway problems are frequently detected, indicating possible transmural 
spread of tumor.  A large tumor mass can cause anterior displacement of 
the membranous portion of the trachea, although this does not necessarily 
imply invasion of the tracheobronchial tree. 
 
     Early findings that do indicate airway invasion include edema and 
elevation of the mucosa with contact bleeding.   Blunting of the carina is 
normally caused by metastatic involvement of the carina by the primary 
tumor mass.  Cytologic sampling of the subcarinal lymph nodes is possible 
by means of transcarinal Needle Aspiration. 
 
5. CT SCAN OF THORAX & ABDOMEN 
 
CT is currently the gold standard radiologic tool for evaluating esophageal 
carcinoma.  The cross sectional imaging technique of CT makes it suitable 
for evaluating the esophageal wall & perioesophageal structures.  It also 
provides useful information about lymph node enlargement and 
concomitantly evaluates the liver, lungs, and adrenal glands for metastatic 
spread. 
 
     It allows one to evaluate the esophageal wall thickness and tumor length.  
Maximum normal esophageal wall thickness is 5 mm, and asymmetric thickening 
is found in more than two thirds of patients with esophageal cancer.  Invasion into 
mediastinum, adjacent structures can be found out.  One criterion of invasion is 
loss of fat plane between the tumor & an adjacent structure. Tracheobronchial 
invasion is predicted with an overall accuracy of more than 85%, the aortic wall 
invasion is predicted with an accuracy of 80%.  
  
     Mediastinal lymph nodes are considered abnormally large, when they are 
greater than 1cm in maximum diameter.  CT is particularly good for detecting 
liver, adrenal, pulmonary and distant nodal metastases. 
 
6. MAGNETIC RESONANCE IMAGING  
 
     Measurement of esophageal wall thickness in the absence of intraluminal air or 
other contrast agents is difficult.  Visualization of the middle third oesophagus is 
complicated by artifacts resulting respiratory & cardiac motion.  It can detect T4 
disease and secondaries.  At the same time, it tends to overstage Lymph node 
involvement and T disease. 
 
7. POSITRON EMISSION TOMOGRAPHY (PET) 
 
     It is a promising investigational approach, which can evaluate the areas for 
increased focal uptake after injection of 18 F- fluorodeoxyglucose.  However, PET 
facilitates selection of patients for operation by detecting distant metastases that is 
not identified by routine conventional radiologic techniques. 
     The sensitivity in detecting secondaries is 80 to 85% and it’s specificity is 92 to 
95%.  Its disadvantages are the nonspecificity of areas of increased cellular FDG 
uptake, inability to determine the ‘T’ stage. 
 
8. SCINTIGRAPHIC TEST FOR METASTASES 
     There is disagreement about the need for scintigraphic evaluationof metastases 
in patients with esophageal cancer.  Bone scans using 99m Tc-labelled methylene 
diphosphonate commonly are used in staging patients with esophageal cancer and 
can be used to detect bone secondaries in asymptomatic patients in the absence of 
elevated serum calcium or alkaline phosphatase levels.  However, the false 
positivity  is found in almost 30% patients. 
 
9. MINIMALLY INVASIVE TECHNIQUES 
     Laparoscopy with or without laparoscopic ultlrasonography has been routinely 
in some centres.  More recently, thoracoscopic staging has been added to the 
staging armamentarium.  Laparoscopic staging permits detection of metastatic 
disease precluding resection in 10 to 20% of patients and is more accurate than 
EUS in abdominal staging.  Thoracoscopic staging is potentially valuable in 
permitting accurate stage assessment prior to any therapy.  Laparoscopy, 
particularly as an initial step before formal resection, is likely to become a widely 
accepted technique for esophageal cancer. 
 
 
10. OTHER STUDIES 
Mediastinoscopy is used by some as a staging procedure for carcinoma of 
upper and middle thoracic esophagus to assess the mediastinal nodal status.   
 
     Percutaneous needle biopsy of suspected extranodal metastases is highly 
accurate and may eliminate the need for open biosy procedure. 
 
     In some cases,  “mini-laparotomy” is of value in documenting metastatic 
spread to subdiaphragmatic sites when suspicious findings are noted on CT scan.  
Kraska & colleagues reported the sensitivity of 80% & specificity of 100% and the 
accuracy  of 93% in detecting Thoracic lymph node by Video-Assisted 
Thoracoscopy (VATS) 
 
TREATMENT 
     Carcinoma esophagus still remains as a lethal disease with poor 5year survival 
rate.  The treatment of patients depends upon the stage of the disease & the general 
condition of the patient.  Most of the cases are at a advanced stage,when it 
becomes symptomatic,precluding  curative surgery. 
Some patients with resectable lesions are unfit for surgery by virtue of 
significant comorbid disease.  The choice of treatment is dependent on its 
morbidity & mortality risk, quality of palliation, risk of recurrence,the availability 
and the experience of particular discipline at the institution where the treatment is 
offered. 
 The therapeutic options include surgery, Radiotherapy, chemotherapy, 
Stenting, Palliative surgeries, or a combination of these techniques.  Current trials 
have focused on radiation and chemotherapy with or without resection.   
 
OPERATIVE TREATMENT 
RESECTION 
     Cervical esophagus 
• Pharyngolaryngoesophagectomy 
• Free jejunal transfer 
 
     Superior Mediastinal 
• Split sternum esophagectomy 
• Three-phase esophagectomy 
 
 
 
 
 
 
     Middle and Lower third 
• Lewis-Tanner operation 
• Transhiatal esophagectomy 
• Three-phase esophagectomy 
• Esophagectomy (left thoracotomy approach) 
 
     Cardia 
• Transhiatal esophagectomy 
• Esophagogastrectomy ( left thoracoabdominal approach) 
• Esophagogastrectomy ( abdominal right chest approach) 
• Abdominal gastrectomy 
 
BYPASS 
• Kirschner gastric bypass 
• Colon bypass 
• Jejunum bypass 
 
 
 
 
 
 
 
 
CURATIVE TREATMENT 
     Factors such as general disability, malnutrition, cardiac risk, multisystem 
dysfunction, liver failure, infection, invasion of a vital structure etc., limit the 
patient’s health and chances of tolerating a curative surgical  procedure.  At best, 
only 50% of patients are eligible for a curative resection at the time of 
presentation. 
 
     Since the lymphatic drainage of esophagus is extensive, both within esophageal 
wall and in the surrounding mediastinal tissues, the longitudinal extension of 
esophageal carcinoma is extensive and of multicentric in origin. 
     Orringer, had proposed  four goals of oesophagectomy; 
1. To relieve dysphagia. 
2. To achieve an operative mortality of less than 10%. 
3. To require hospitalization of less than 14 days. 
4. To minimize the late complications and morbidity. 
If an esophagectomy is indicated, three major technical approaches are available. 
1. Transthoracic esophagectomy. 
2. Transhiatal esophagectomy. 
3. En-bloc Radical esophagectomy. 
Although no consensus has been formed on the preferred technique, Transthoracic 
esophagectomy is preferred by most thoracic surgeons.  Since 1970, the reported 
5-year survival rates for patients undergoing esophagectomy have risen from an 
average of 10 to 15% to a high 35% secondary to refinements in surgical 
techniques, improved anaesthesia and critical care management, and an emphasis 
on nutrition by enteral and parenteral routes.  
 
     Despite these improvements in surgical outcome, the overall survival rate for 
carcinoma of esophagus has changed little, Katlic and colleagues noted only an 
11% 5-year survival rate in patients with locally advanced N1 disease (Stages IIB 
or III) who were treated in 1990s. 
 
     Regardless of technique, Surgeons, generally agree on the desirability of a so-
called R0 resection (i.e., a complete macroscopic and microscopic removal of 
tumor as the basic requirement in surgery with curative intent for carcinoma of 
esophagus and Gastroesophageal junction).Great controversy remains on the 
extent of the resection and the type of surgical access (i.e., Transthoracic, left or 
right sided, or Transhiatal resection). Reports from Japanese groups focus on the 
value of extended lymphadenectomy both in the mediastinum and in the superior 
abdominal compartment (two-field lymphadenectomy). 
 
     Many surgeons think that adding bilateral cervical lymphadenectomy ( three-
field lymphadenectomy) is essential, especially in patients with supracarinal 
tumors.  As expected, these extensive resections and reconstructions may cause 
surgical morbidity and mortality.  However, even in patients with advanced Stage 
III disease, 5-year survival rates of around 20% can be obtained after an R0 
resection.   
TRANSTHORACIC ESOPHAGECTOMY 
1. The traditional surgical approach to distal esophageal carcinoma has been a 
left-sided thoraco-abdominal incision. 
2. The distal esophagus, proximal stomach and adjacent lymph node bearing 
tissues are resected, and an intrathoracic esophagogastric anastamosis is 
performed. 
3. A gastric drainage procedure ( Pyloromyotomy or Pyloroplasty) is 
recommended to prevent subsequent PostVagotomy Gastric Outlet 
Obstruction from Pylorospasm. 
 
DISADVANTAGES 
1. Combined thoracic and abdominal operation in a debilitated patient may 
lead to respiratory insufficiency, resulting from postoperative incisional 
pain and an inability to breath deeply, that requires prolonged mechanical 
ventilatory assistance and often causes death. 
2.  Disruption of an intrathoracic esophageal anastamosis results in 
mediastinitis and sepsis, fatal in 50% of the patients. 
3. Intrathoracic esophageal anastamosis is inadequate in providing long-
term relief of dysphagia either because of anastamotic suture-line tumor 
recurrence or because of the development of reflux esophagitis above the 
anastamosis. 
4. Intrathoracic esophagogastric anastamoses are almost invariably 
associated with the development of reflux oesophagitis, which follow 
disruption of the LES mechanism. 
5. The operative mortality varies significantly, ranging from as high as 14% 
to as low as 2.2%. 
EN BLOC ESOPHAGECTOMY 
     Because many patients present with metastases to regional lymph nodes as well 
as to the surrounding tissue and organs, a more radical resection, the en bloc 
esophagectomy, has been advocated by a few thoracic surgeons.  An envelope of 
normal tissue is removed along with the spleen,celiac nodes, posterior 
mediastinum, azygos vein, thoracic duct, and adjacent diaphragm.  
 
     With this aggressive surgery, operative mortality ranges from 5.1 to 11%, not 
significantly different from other approaches.  The two major complications are 
similar to Transhiatal and Transthoracic esophagectomies; anastomotic leak and 
respiratory complications.  With the en bloc technique, 5-year survival rate is 40 to 
55% for patients with Stage I adenocarcinoma confined to the esophageal wall. 
 
TRANSHIATAL ESOPHAGECTOMY 
     In performing a transhiatal esophagectomy, the surgeon removes accessible 
cervical, intrathoracic, and intra-abdominal lymph nodes for staging, but a 
complete en bloc resection of adjacent lymphnode bearing tissue is not 
accomplished. 
      It is performed through an upper midline abdominal and cervical incision 
without thoracotomy, therefore, the thoracic esophagus is resected through the 
widened diaphragmatic hiatus and the neck.  The stomach is mobilized by dividing 
the left gastric and left gastroepiploic vessels and the right gastric and the right 
gastroepiploic arcades are preserved.  Pylomyotomy and feeding jejunostomy 
are performed routinely.   
 
     The entire thoracic oesophagus from the level of the clavicles to the cardia is 
resected, while one carefully monitors intra-arterial blood pressure to avoid  
prolonged hypotension resulting from cardiac displacement.  The surgical stapler 
is used to fashion a gastric tube from the greater curvature of the stomach, while 
preserving the entire length.  The stomach is mobilized through the posterior 
mediastinum in the original esophageal bed and is anastamosed to the cervical 
oesophagus.   
 
     For distal-third esophageal tumors localized to the cardia, the high lesser 
curvature of the stomach is resected 4 to 6cm beyond the gross tumor, while 
preserving the point on the high greater curvature that reaches cephalad  for the 
cervical esophagogastric anastamosis.  Critics of THE object to the limited 
exposure afforded by the hiatus to the intrathoracic oesophagus.  The limited 
exposure potentially increases the risk of uncontrollable haemorrhage, however, 
the peroperative blood loss is significantly lower than that of Tranthoracic 
oesophagectomy. 
 
     Contraindications to this procedure includes evidence of tumor invasion of 
the pericardium, aorta, tracheobronchial tree. 
 
THORACOSCOPIC ESOPHAGECTOMY 
     Several authors have reported the use of Video-Assisted Thoracoscopy or 
Laparoscopy in performing esophagectomy.  Techniques described include a 
standard laparotomy with Thoracoscopic mobilization of the esophagus used to 
complete the operation, a totally laparoscopic Transhiatal technique, laparoscopic 
gastric mobilization with a right mini-thoracotomy, and the combined laparoscopic 
and thoracoscopic technique with thoracoscopic mobilization of the esophagus, 
followed by laparoscopic gastric mobilization. 
 
     Advantages of Thoracoscopic esophageal mobilization over Thoracotomy or 
laparotomy with Transhiatal dissection have not been clearly demonstrated in 
these studies. 
 
RECONSTRUCTION AFTER ESOPHAGECTOMY 
After portion of the oesophagus is removed, or after complete 
esophagectomy, a conduit must be established for alimentary tract continuity. The 
stomach, colon, and jejunum have all been successfully used as esophageal 
substitutes, but the stomach appears to be the conduit of choice because of it’s 
ease in mobilization and ample vascular supply.   
 
       A higher incidence of mortality is noted with the use of colon because of the 
necessity for three anastomoses (coloesophagostosmy, colojejunostomy, and 
colocolostomy).  Jejunal loops can also be used, but their limited vascular supply 
restrict mobility & reach. 
RADIATION THERAPY 
      Patients who undergo External-beam radiataion therapy, used alone in the 
treatment of esophageal carcinoma, have only a 5 to 10% 5-yeat survival, so this 
therapy is not considered curative.  Radiation therapy has low morbidity and can 
relieve esophageal obstruction in most patients in 4 to 7 days.  The relief of 
dysphagia is short lived, and recurrence is seen usually within 6 months.  The goal 
of radiation therapy is to destroy the tumor, its microscopic extensions & other 
local sites of metastases without crossing the radiation threshold of normal 
adjacent cell. 
 
     The target includes a 5 cm margin on either side of the tumor and adjacent 
lymph node stations.  The supraclavicular or celiac lymph nodes  are targets if the 
tumor is in the upper or lower oesophagus, respectively.  In the chest, the critical 
structures are the lung, spinal cord, bone marrow.  Typically,  custom-moulded 
casts or cradles are used to achieve immobilization and reproducibility. 
 
     Treatment can be given by hyperfractionation, accelerated fractionation, or 
conventionally.  The range is from 5000 cGy in 20 treatments over 4 weeks to 
6600 cGy in 33 treatments over 7 weeks.  Some of the complications seen are 
pneumonitis, pericarditis, myocarditis, stricture, fistula formation and spinal cord 
damage.  Radiation therpy is contraindicated in the presence of a TEF.   Radiation 
necrosis of tumor promotes fistula formation when the tumor has penetrated the 
trachea or bronchus. 
 
CHEMOTHERAPY 
     Chemotherapy as a single modality in the treatment of esophageal cancer is the 
least effective strategy.  Although radiographic improvement can be seen in up to 
one-half of patients, two or three  cycles ( 6 to 12 weeks ) of chemotherapy are 
required , relief of dysphagia is slow and/or incomplete, and survival is anecdotal.  
Unfortunately, no reliable method exists to identify ”responders” before therapy is 
begun.  Chemotherapy is used pre-operatively alone or in combination with 
radiation therapy to treat micrometastases and to reduced the size of the tumor to 
improve resectability rate. 
 
     Moreover, if surgery is not appropriate, chemotherapy is used with radiation 
therapy for palliation and possibly to improve survival.  It is typically given in a 
combination of two or more drugs.  Cisplatin and 5-Fluorouracil are the most 
frequently used agents.  Other agents with activity in esophageal cancer include 
Paclitaxel, Camptothecin, Irinitecan and Vinorelbine.  Combination therapy 
has been promising, with response rates between 50 and 70% for Cisplatin based 
doublets.  Adding a third agent, such as a Vinca alkaloid , Bleomycin, or 
mitoguazone has only fractionally improved response while almost universally 
worsening toxicity. 
 
     Most studies dealing with neoadjuvant therapy are based on combinations that 
contain Cisplatin, which seems to be well tolerated without increasing the post-
operative mortality or morbidity rates.  Response rates vary between 25 and 50%.  
Meluch and colleagues treated 49 patients with localized esophageal cancer with 
Paclitaxel, Carboplatin, and continuous low-dose Fluorouracil given with 
concurrent Radiotherapy.  Forty six percent of the operated patients achieved a 
pathologic complete response, and an additional 30% were found to have only 
microscopic residual disease in the resected specimen.    
 
PALLIATIVE TREATMENT 
     Palliation is appropriate when patients are too debilitated to undergo surgery or 
have a tumor that is unresectable because of extensive invasion of vital structures, 
recurrence of resected or irradiated tumor, and\or metastases.  The goal of 
palliation is to use the most effective tumor and least invasive means possible to 
relieve dysphagia and discomfort, to support nutrition, and to limit hospitalization. 
 
     Depending on the perceived life expectancy, palliation includes Dilatation, 
intubation, Photodynamic therapy, Radiotherapy with or without 
chemotherapy, surgery, and\or laser therapy.  None of these methods have 
proven superior. 
 
DILATATION 
     It is to palliate dysphagia and to allow endoscopic evaluation with a 2 to 3% 
risk of esophageal wall rupture or bleeding.  Unfortunately, relief is measured only 
in weeks.  Patients with high-grade malignant strictures more likely present with 
advanced disease. 
 
STENTING 
     The purpose of a stent is to bridge the obstruction in the esophagus to allow 
luminal patency primarily to prevent pooling of saliva and secondarily for 
nutrition.  Flexible, self-expanding stents are constructed of two layers of super 
alloy monofilament wire with a layer of silicon between them.  The silicon 
sandwitched between the layers delays tumor in-growth through the holes in the 
wire mesh.   
 
     After administration of local or general anaesthesia, the stricture is dilated to 42 
to 45 French, the lesion is identified, and the expandable covered stent is inserted 
under fluoroscopic or endoscopic control.  Once the stent is inserted   
and expanded, the ends flange out to anchor to the wall of the esophagus. 
 
PHOTODYNAMIC THERAPY 
     For photodynamic therapy, a photosensitizer such as dihematoporphyrin ether, 
is given intravenously and after 2 to 3 days is retained in the tumor in a much 
higher concentration than in healthy tissue.  Then, a low power Laser system that 
produces red light is delivered to the tumor by a flexible endoscope.  
  
     Two to three days after this therapy, esophagoscopy is repeated and the 
necrotic tissue is removed, often monthly.  Complications include development of 
fistulas and aspiration.  Edema of the hands & face, sensitivity to light are other 
complications.  
  
MATERIALS AND METHODS 
     This is a prospective study of 160 patients ( out of 2260 cancer patients), of 
Carcinoma Oesophagus, who were admitted in the Thanjavur Medical College 
Hospital, from June 2004 to September 2006. 
 
METHODS 
     The methods include, obtaining the important information from the patients 
through History, thorough clinical examination and doing the investigations, 
whatever is necessary to aid the diagnosis and resectability.   
 
     All the informations were entered in a Proforma, specially designed for this 
study. 
 METHODOLOGY 
     The following factors were taken into consideration while evaluating the 
patients. 
• Age and sex incidence. 
• Geographical factors. 
• Socio-economic status. 
• Personal habits. 
• Symptoms and duration.  
• Predisposing factors. 
     In all these patients, nourishment was noted.  Abdomen was examined for any 
mass, hepatomegaly and ascites.  Rectal Examination was done to find out 
Bloomer’s shelf or deposit in the Pouch of Douglas.  Respiratory system was 
examined to find out pleural effusion and signs of Aspiration pneumonia. 
 
They were all subjected to basic investigations which included, 
1. Urine Albumin\Sugar 
2. Blood Hemoglobin. 
3. Blood Sugar. 
4. Blood Urea. 
5. Serum Creatinine. 
6. X-Ray chest. 
Specific Investigations such as  
1. Upper GI Endoscopy and Biopsy. 
2. Barium Swallow. 
3. Ultrasound Abdomen. 
4. CT Thorax and Abdomen. 
     Upper GI Endoscopy was done in all the patients and the biopsy was taken 
from the growth.  The presence, location, type of growth and it’s distance from 
Incisors were studied. 
 
 
     All patients who had a positive endoscopy and biopsy were submitted for 
Ultrasound of the abdomen to rule out any metastases. 
 
     CT Thorax was done to study the location of tumor, esophageal wall thickness 
and the tumor length.  The presence of mediastinal lymphadenopathy and the 
direct invasion of adjacent vital structures like Trachea, Aorta, heart etc., are noted 
and hence the resectability was noted. 
 
     CT Abdomen revealed the presence the hepatic, Adrenal secondaries. 
 
     Bronchoscopic examination was done in all the patients to rule out 
tracheobronchial involvement by the primary tumor. 
 
     After obtaining the essential informations from these studies, the surgical 
management in the form of Transhiatal esophagectomy was planned in selected 
50 patients, excluding the remaining patients . In our Institution, Transthoracic 
esophagectomy is not practiced. 
 
 
 
 
EXCLUSION CRITERIA 
1. patients with carcinoma involving the cervical \ Upper 3rd esophagus. 
2. patients with extensive disease. 
3. patients with distant metastasis. 
4. patients with infiltration of perioesophageal vital structures, precluding 
respectability. 
5. patients with co-morbid conditions like Anaemia, CCF, CAHD etc., 
6. patients with poor general condition. 
7. patients not willing for surgery. 
     The selected 50 patients were pre-operatively evaluated thoroughly and their 
general condition was improved. Out of 50 patients, per-operatively, we found 
that, in about 25 patients the tumor was found to be unresectable due to  several 
causes like, extensive disease, invasion of adjacent vital structures, multiple 
peritoneal seedlings, small hepatic secondaries etc. Hence these (25) patients were 
submitted to Palliative Radiotherapy, Feeding Jejunostomy, Stenting. 
     With the facilities available, we adopted Transhiatal oesophagectomy in the 
remaining 25 patients as the curative surgical procedure with or without 
postoperative chemo\raditherapy. 
     Post operative complications were identified promptly and managed 
accordingly.  Most of the patients who were operated were reviewed in our OP 
Department.  Every attempt was made to evaluate the general condition, any 
evidence of recurrence, distant metastasis, while following up the patients. 
                                
                             OBSERVATIONS AND RESULTS 
 
     The incidence of carcinoma esophagus, by this study in our institution is 7.0%  
( 160 \ 2260 ) 
                                           AGE INCIDENCE 
AGE GROUP 
(YEARS) NUMBER OF CASES PERCENTAGE
< 30 00 0% 
31 – 40 19 12% 
41 – 50 51 32% 
51 – 60 77 48% 
61 – 70 13 08% 
> 70 00 00% 
 
  Regarding the age of the patients, the youngest patient with carcinoma of 
esophagus in our institution was about 30 years, a female and the oldest was a 69 
year old male.  
     Most of the patients affected were in the age group between 51 to 60 (48%) 
which correlates well with the Orringer et al., studies. 
 
                                          
 
 
 
SEX INCIDENCE 
MALES FEMALES AGE GROUP 
  (YEARS)         NUMBERS % NUMBERS % 
<30 00 0% 00 0% 
31-40 09 9% 07 11% 
41-50 30 32% 21 33% 
51-60 48 50% 29 44% 
61-70 09 9% 07 11% 
>70 00 0% 00 0% 
Total 96 100% 64 100% 
 
                                    
    In our study, males were more commonly affected, about 96 patients.                    
The male  :   Female ratio is 1.5 :1.  
 
     It is well known that carcinoma of esophagus afflicts more number of patients 
in the low socioeconomic status.  Regarding this, close to 100% of the patients 
were of the lowest socioeconomic status.  This is mostly due to the fact that people 
seeking medical advice at Government based institutions are usually of the lower 
income group. 
     While evaluating the geographical distribution of the carcinoma of the 
esophagus, we found that as far as the cases referred to the TMCH, were 
concerned the maximum number of patients from the place  Trichy (29).  It 
accounts for about 18.12% of the patients. 
 
The relation of carcinoma of esophagus and personal  habits has been well 
established in various studies. 
FEMALES 
HABITS  
NUMBERS % 
CHEWING TOBACCO 70 44% 
 BETEL NUT 64 40% 
 BOTH 80 50% 
SMOKING  70 44% 
ALCOHOL  62 39% 
BOTH  86 54% 
HOT SPICY 
FOOD 
 88 58% 
 
    The majority of patients had the habit of consuming hot spicy foods, 
corresponding to about 58%.  About 54% of patients were both  alcoholic and 
smokers.  About 44% of patients were smokers and about 39% were alcoholics. .  
The alcoholism and smoking are considered as the important carcinogens. 
     About 44% patients were tobacco chewers and 40% had the habit of Betel nut 
chewing.  These habits were found to be common in females. 
 
 
 FACTORS 
 
 
NUMBER OF 
CASES 
 
PERCENTAGE 
STRICTURES 4 2% 
BARRETTS 7 4% 
IRRADIATION 0 0% 
PV SYNDROME 4 2% 
TYLOSIS 4 2% 
PREVIOUS 
GASTRIC 
SURGERY 
0 0% 
 
 
     Considering the other predisposing factors, very negligible numbers only could 
be documented.  Only four patients had stricture, seven patients were previously 
diagnosed to have Barretts esophagus.  The Plummer Vinson Syndrome and 
Tylosis were present in four patients in each.  None had a previous history of 
irradiation of any sort or a past gastric surgery. 
 
     The distribution according  to the presenting complaints are given by the 
following symptomatology; 
 
COMPLAINTS NUMBER OF CASES PERCENTAGE 
    DYSPHAGIA 140 88% 
   WEIGHT LOSS      115 72% 
   ANOREXIA                   108             68% 
   VOMITING 51 32% 
   CHEST PAIN 45 28% 
   ODYNOPHAGIA 42 26% 
   COUGH 32 20% 
   ANOREXIA 108 68% 
   HOARSENESS 0 0% 
   DYSPNOEA 0 0% 
 
     Among the presenting complaints, the commonest and in many a times, the 
only complaint was dysphagia ( 88% ).  The second most complaint was the 
recent weight loss, which was present in about 72% of patients.  About 68%, had 
loss of appetite.  Rarely, patients had the hematemesis ( 16% ). No patient had 
hoarseness of voice or dyspnoea. 
 
 
 
 
Distribution of cases according to the site of the tumor; 
 
  LOCATION NUMBER OF CASES PERCENTAGE 
UPPER 1\3 30 19% 
MIDDLE 1\3 48 30 % 
LOWER 1\3 82 51% 
 
     There was a considerable variation in the statistics as far as the location of the 
tumor is considered.  The commonest site of the carcinoma of esophagus was the 
lower 3 rd in our institution, about 82 which accounts for 51% and the middle 3rd 
growths corresponded to about 30% in 48 patients.  About 19% had upper 3rd 
carcinomas, which were absolutely excluded from our study. 
 
     Various studies have documented a major shift in the histological pattern of the 
cancer esophagus, with a double fold rise from a traditional squamous cell 
carcinoma to adenocarcinoma over the last few decades.  But, observations made 
in our study results do not correlate well with the changing trend as far as the 
histological pattern is concerned.  The commonest histological pattern is still 
Squamous cell carcinoma in our institution. 
      
 
 
                                 OGD SCOPY FINDINGS 
TYPEOF GROWTH NUMBER OF CASES PERCENTAGE
FUNGATING 0 0% 
ULCERATIVE 83 52% 
INFILTRATIVE 64 40% 
POLYPOID 13 08% 
 
     Most of the patients were found to have ulcerative growths.  Infiltrating type of 
growths were the second common type of growth.  Rarely, about 8% had polypoid 
growth.  
                              
                                   HISTOLOGICAL VARIETIES  
TYPE NUMBER OF CASES PERCENTAGE
SQUAMOUS CELL 115 72% 
ADENOCARCINOMA 39 24% 
NOT SPECIFIED 06 04% 
         
     Some lesions when biopsied were reported to as a specific type. some were 
given as lesions highly suspicious of malignancy.  These have been included 
under the group as not specified. 
      
Of 160 patients, the 50 patients were selected by adopting the exclusion criterias. 
   FACTORS NUMBER OF CASES % 
   UPPER 1/3 rd GROWTH 30 18.75% 
   EXTENSIVE DISEASE 48 30.00% 
   DISTANT METASTASES 11 06.87% 
   CO-MORBID ILLNESS 08 05.00% 
   POOR GENERAL CONDITION 10 06.25% 
   NOT WILLING FOR SURGERY 03 01.87% 
   
   Since the aim of this study is to highlight the role of Transhiatal esophagectomy 
(THE), the carcinomas involving the cervical esophagus  were primarily excluded.  
About 48% of patients had advanced disease at the time of their initial 
presentation, which may be explained by the biological behaviour of the disease.  
Distant metastases were found in 11 patients (06.87%). 
 
     About 8 patients ( 5%) had comorbid illnesses like Ischemic Heart disease 
(3patients), Atrial fibrillation (2 patients), Complete heart Block (2 patients), 
COPD ( 1 patient ) and hence they were excluded.   Nearly 10 patients had very 
poor general condition, which made them unfit for surgery.  After explaining the 
risks of surgery, 3 patients (1.87% ) were not willing for surgery.  All the excluded 
patients were referred to the Radiotherapy Unit for further management. 
     Out of 50 selected patients, only 25 patients were found to have resectable 
growths.  The following were the factors which precluded from doing THE 
preoperatively. 
         FACTOR NUMBEROF CASES PERCENTAGE 
  EXTENSIVE DISEASE 08 16% 
  PERIOESOPHAGEAL 
  INVASION 
07 14% 
  HEPATIC    
  SECONDARIES 
06 12% 
  PERITONEAL   
  SEEDLINGS 
04 08% 
Inspite of thorough preoperative evaluation with Barium Swallow, 
 OGD Endoscopy, CT Thorax and USG Abdomen, we found extensive disease in 
about 16 patients (16%), invasion \ infiltration into trachea , Azygos vein in 7 
patients (14%), small hepatic secondaries in 6 patients (12%) and multiple  
Omental and peritoneal seedlings in about 4 patients (8.0%). 
These patients were further managed as following; 
  TREATMENT NUMBER OF CASES PERCENTAGE 
   T H E 25 50% 
  RADIOTHERAPY 15 30% 
      
   STENTING 
04 08% 
  JEJUNOSTOMY 06 12% 
      The preoperatively found unresectable patients were managed with palliative 
Radiotherapy (15 patients), Feeding Jejunostomy ( 6 patients), 
Referred to higher centres for  Palliative Stenting ( 4 patients). 
     Complications of the surgical procedure are usually less serious and could be 
managed conservatively and none required a repeat surgery. 
COMPLICATIONS NUMBER PERCENTAGE
  WOUND INFECTION 03 12% 
ANASTOMOTIC LEAK 04 16% 
STRICTURE 03 12% 
WOUND DEHISCENCE 00 0% 
CHYLOTHORAX 00 0% 
HEMOTHORAX 03 12% 
VOCALCORD PALSY 01 04% 
PNEUMONITIS 02 08% 
INTESTINAL OBSTRUCTION 00 0% 
DEATHS 02 08% 
 
     The cervical anastamotic leak is present in 4 patients (16%) which had resolved 
with conservative management.  About 3 patients (12%) had stricture, who were 
submitted to repeated Endoscopic dilatations.  Three patients ( 12%) had 
hemothorax and two (8.0%) had pneumonitis, which were managed 
conservatively.  One (4.0%) had vocal cord palsy, which could be due to 
accidental injury of Recurrent Laryngeal Nerve during blunt thoracic dissection. 
 
     The post-operative mortality was 8.0% ( 2 patients), out of which one had 
Myocardial Infarction and another had Atrial Fibrillation.    However, 7 
patients (24%) had an uneventful postoperative period.                        
Follow up periods of the patients were variable. 
    PERIOD NUMBER PERCENTAGE 
  <1 MONTH 08 32% 
1-3 MONTHS 10 40% 
4-6 MONTHS 15 60% 
7-9 MONTHS 12 48% 
10-12 MONTHS 08 32% 
1-2 YEARS 04 16% 
 > 2 YEARS 03 12% 
LOST FOR 
FOLLOW-UP 
06 12% 
 
     Patients who underwent incomplete treatment are also included in the group for 
lost follow-up.  The mean period of follow-up was 7.6 months.  
  
 
    Recurrence of the disease in the form of adenopathy, visceral secondaries or 
recurrence at the previous site were also registered. 
 
 RECURRENT DISEASE NUMBER % 
     AT THE SITE 06 12% 
     LYMPH NODE 02 04% 
     VISCERAL  
           SECONDARIES 
03 06% 
 
     Restenosis is being considered as recurrent disease at the site.  These patients 
were managed with Radiotherapy. 
 
                                                    
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
EPIDEMIOLOGY, SEX AND AGE INCIDENCE 
      The epidemiological characteristics of esophageal carcinoma are unusual, 
since its incidence in different geographic areas is extremely variable, with the 
greatest differences recorded for all tumors.  The incidence of  esophageal 
carcinoma varies from 8.1% recorded at the Chennai registry to 4.6 at Delhi. The 
incidence as per the surveillance made by the National Cancer Registry Project 
(NCRP)  quotes an incidence of 8.6% at Bangalore and 6.8% at Mumbai.  The 
incidence of carcinoma esophagus in our institution is 0.07%, which is relatively 
lower. 
 
     As per the  study, the rise in esophageal cancer commences in the thirties and 
peaks in the 5th decade.  Studies conducted both in India and abroad, show peak 
incidence in the 7th and 8th decades.  The exact cause of this difference in this 
regard is not known. 
 
ETIOLOGY AND RISK FACTORS  
     All the patients in our study, who presented with esophageal carcinoma were of 
the lower socioeconomic group.  Day and Munoz,   1982 and Schottenfeld 1984, 
and several other series have shown an association between esophageal cancers 
and low socioeconomic status. 
     Low levels of retinol, riboflavin, Ascorbic acid, and alpha-tocopherol are 
prevalent in the population of Linxian, China, where esophageal cancer is 
epidemic.  In Japan, poor food variety has been identified as a risk-enhancing 
factor and combinations of fruits, vegetables and fresh meat appear to be risk-
reducing factors.  
 
     De Carli et al 1989    had stated that low intake of fruits, particularly citrus 
fruits and accordingly, reduced  Vitamin C intake has been repeatedly associated 
with an increased risk of esophageal cancer.  Deficiencies in various mineral 
elements such as selenium, Zinc, Molybdenum also have been cited as possible 
etiologic factors.  
 
     Francheschi et al 1990  discovered that the deficiencies are believed to make 
one more susceptible to the carcinogenic  effects of exogenous factors. 
 
     From the data given in our study there is a strong association between the use 
of tobacco in both of its forms of usage viz., chewing and smoking and the 
development of esophageal cancers. 
 
     The most important risk factors for cancer of esophagus in developed countries 
are cigarette smoking  (IARC 1986)  alcohol consumption (IARC 1988).The 
associations between cigarette smoking, alcohol consumption and esophageal 
cancer are difficult to separate, largely because of the correlation in the two 
exposures and their mutual associations with the risk of cancer esophagus. 
     The risk of esophageal cancer has also been shown to be increased among non-
tobacco smokers who consume alcohol and among non-drinkers of alcohol who 
smoke tobacco (La Vecchia and Negri 1989). 
 
     The role of alcohol consumption was not clearly demonstrated in the French 
Department of Ille-et-Villaine where the risk rose steadily with the amount of 
alcohol consumed (Tuyns et al 1077) 
 
     The risks associated with tobacco use appear to increase with the number of 
cigarettes smoked per day, duration of smoking, and tar content. (Tuyns et 1979 ; 
Rossi et al 1982 ;  Yu et al 1988).      
 
    A synergistic effect for the combined habit of alcohol drinking and tobacco 
smoking or chewing has also been reported. 
 
MORPHOLOGICAL TYPE AND LOCATION 
     The predominant histomorphology our study was the squamous cell carcinoma 
which accounts for about 72% of the toal oesophageal cancers at the TMCH.  In 
Europe, the incidence of adenocarcinoma rose to double fold in the 1990s.   
 
     Steiger et al 1987, stated that Primary Adenocarcinoma represent 3 to 8% of 
the esophageal cancer.  Observations made in our study also show a rise in the 
incidence of adenocarcinoma.  It accounts for about 24% of the  esophageal 
cancers. 
 
     Esophageal cancer is usually located in the middle third in about 50% of the 
cases; the lower thoracic and upper thoracic esophagus are involved in a similar 
percentage of cases and the cervical esophagus is involved less frequently. (Guili 
and Gignoux 1980)   
 
     In our study, we found that the most commonest site of the tumor is the lower 
third which corresponded to about (51%), while middle third was the commonest 
site in about 30% of patients. A few patients had growth involving the upperthird ( 
9% ) 
 
SURGICAL THERAPY 
     In the past, esophageal surgery was burdened by high operative morbidity and 
mortality rates, the highest known in surgery (Lauois et al 1983).  There has been 
a remarkable reduction in these rates in the last 10 years.   
 
     The pre-operative care of a patient who has to undergo esophagectomy should 
include a prophylaxis for any post-operative complications, particularly regarding 
respiratory problems.  Smoking should be stopped at least 10 days before surgery 
and in the presence of pulmonary problems, physiotherapy  is advisable together 
with pre-operative bronchodilatation treatment.  If the patient presents with 
malnutrition, hypercaloric parenteral nutrition or tube enteral feeding, at 2500 to 
3500 calories\day, is advisable for a period of 7 to 10 days (Moghissi et al 1977) 
 
     The selection of patients for Transhiatal esophagectomy is very important in 
computing to the outcome.  Most of the time it depends upon the general condition 
(if operable) of the patient and the tumor stage (if resectable).   
 
     Usually the lower third esophageal growths and the lower half of the middle 
third (subcarinal) growths are the suitable growths for Transhiatal esophagectomy. 
 
     The contraindications for esophagectomy can be relative to the patient or to the 
tumor.  At present, an elderly patient (Peracchia et al. 1988), the length of the 
tumor and the concomitance of Child-A risk liver cirrhosis (Fekete et al 1987) are 
not considered absolute contraindications for surgery.  
 
SURGICAL APPROACH 
     Transhiatal esophagectomy without Thoracotomy (Orringer et al 1993) has 
been performed by an increasing number of authors in recent years.  It is 
performed by isolating the mediastinal esophagus through a cervicotomy and 
laparotomy (Orringer et al 1984, 1987).  We at the TMCH, have adopted this 
technique in the selected patients, since it reduces the time  of the operation 
compared with transthoracic esophagectomy and allows surgery to be performed 
on patients who would not tolerate a thoracotomy. 
 
     In our experience, this surgery seems to be properly indicated for cancers of 
lower third intrathoracic esophagus and for selected cardial cancers. 
    
  Akiyama et al 1978  stated that stomach is the viscus of choice to replace the 
esophagus resected for cancer.  It is isolated and tubulized before transposition.  
We do agree with the statement, since stomach tubulization allows removal of the 
lymph nodes located the left gastric vessels, a possible metastasis station, 
improves the gastric vascularization and avoids mediastinal encumbrance which is 
possible when the whole stomach is transposed. 
 
     Interpositioning of a colonic segment and the transposition of a Roux-en-Y 
loop of jejunum was also done on two cases of lower esophageal cancer at TMCH.  
The results were not encouraging.  This was partly due to fact that patients were 
not able to tolerate this long duration procedures. 
 
     Esophagogastric anastomosis is performed in our institution only by using hand 
sewn techniques. 
     Wong et al 1987  identified that the main post-operative complication is the 
anastomotic leakage.  The anastomotic leak rate in our cases is well within 
acceptable range.  It was about 16% (4\25) 
  
RESULTS OF SURGICAL RESECTION 
     Contrasting data regarding the resectability rates and the long-term survival 
rates are reported in the literature.  This is because there are very different 
therapeutic attitudes in the various centres ; that is, aggressive of conservative, 
varying criteria for the selection of the patients for the different types of treatment 
and a multiplicity of therapeutic protocols and schemes. 
 
     At present, the most experienced surgical teams report a postoperative 
mortality rate below 5 – 10% (Peracchia et al 1988; Muller et al. 1990) 
     Observations made in our study report a mortality rate of about 8.0%. 
POST-OPERATIVE MORTALITY 
STUDIES PERCENTAGE 
   KATARIYA et al 6.7% 
    MOON et al 7.3% 
   MICHIGAN UNIVERSITY 7.2% 
   GOLDMINC et al 6.4% 
   BOLTON  et al 5.9% 
   SCHAKELFORDT et al 5.7% 
   ORRINGER et al 4.0% 
   OUR STUDY 8.0% 
 
     In our study, the cervical anastomotic leak was present in about 12% of patients 
which were managed conservatively. 
PERCENTAGE 
STUDIES ANASTOMOTIC
LEAK 
STRICTURE
 
KATARIYA et al 15.1% 14.1% 
GOLDMINC et al 14.0% 16.0% 
MICHIGAN UNIVERSITY 12.0% 13.5% 
SCHEKELFORDT et al 13.5% 14.6% 
ORRINGER et al 07.9% 09.0% 
OUR STUDY 16.0% 12.0% 
 
              About 12% of our patients had post-operative strictures, who were 
managed with enodoscopic dilatation. Incidence of  both the anastomotic leaks and 
strictures in our study are well comparable with the international literature.  These 
complications are relatively less in Transhiatal esophagectomy. 
PERCENTAGE 
STUDIES VOCALCORD 
PALSY       
CHYLOTHORAX
KATARIYA et al 11.3% 0.71% 
GOLDMINC et al 10.5% 0.6 % 
MICHIGAN 
UNIVERSITY 
9 % 0.5% 
SCHEKELFORDT et al 8.6 % 0.7 % 
ORRINGER et al 19.2 % 0.2 % 
OUR STUDY 4 % 0 % 
                               
              We found vocal cord palsy (4%), post-operatively, which can be 
explained by the probability of accidental injury during blind thoracic dissection. 
No patient had Chylothorax, in our study. 
PERCENTAGE 
 STUDIES PULMONARY    CVS 
KATARIYA et al 50 % 11.9 % 
GOLDMINC et al 34 % 12 % 
MICHIGAN 
UNIVERSITY 
12  % 16.0 % 
SCHEKELFORDT et al 36  % 09.8  % 
ORRINGER et al 19.2 % 0.2 % 
OUR STUDY 8 % 8 % 
                                                        
     The pulmonary complications were in the form of pneumonitis, which were 
managed with higher antibiotics.  Two died of Cardiovascular complications, one due 
to Myocardial Infarction, another due to Atrial Fibrillation. 
 
     About 3 of the 25 patients, who were offered surgical treatment are alive after 2 
years which accounts for about 16%.  This figure, actually, represents the actual 
number of patients cured of the disease.  About 4 (16%) are alive after one year 
without any evidence of recurrent disease or other complications . 
PERCENTAGE 
STUDIES 
ONE YEAR TWO YEARS 
KATARIYA et al 26.2  % 14.8 % 
GOLDMINC et al 29.7  % 19.7  % 
MICHIGAN 
UNIVERSITY 
25.4  % 17.2  % 
SCHEKELFORDT et al 31  % 18.5  % 
ORRINGER et al 33.7  % 21.6 % 
OUR STUDY 20.01  % 16  % 
   
     
        Since our study is of short duration ( 2 1\2 years) we are unable to calculate the  
5 year survival rate.  The actual 5 year survival rate after curative esohagectomy 
varies from 15% to 30% on the basis of tumor stage.  Combining T H E with 
Thoracoscopic Lymphadenectomy may improve survival and needs evaluation by a 
trial. 
 
CONCLUSION 
 1.     Carcinoma esophagus is one of the most important leading sites of cancer in 
our country. 
 
2.     It is one among the cancers that have increased male : female ratio. 
 
3.     Carcinoma esophagus is more common in lower socioeconomic group. 
 
4.     The predominant histomorphology is Squamous cell carcinoma. 
 
5.     Carcinoma is more common in the lower 3rd esophagus and it is rare in the upper 3rd. 
 
6.     There is a significant rise in the incidence of Adenocarcinoma. 
 
7.     A strong association exists between carcinoma esophagus with smoking and  
        alcoholism. 
 
8.     The Transhiatal esophagectomy scores significant role in the surgical  
        management of lower 3rd and lower half of the middle 3rd growths. 
 
9.     The T H E avoids the risks of Thoracotomy  and minimizes the hospital stay. 
 
10.   TransHiatal esophagectomy carries less postoperative complications, do not 
        need mechanical ventilatory support. 
 
11.   Both Intra-operative and Post-operative mortality is less. 
 
12.   Signifcant 1 year and 2 year survival rates can be achieved with this surgical          
        procedure.          
 
 
 
 
 
 
 
 
PROFORMA 
 
NAME                                           AGE                                    SEX 
OCCUPATION                            I.P NO.                                UNIT \ WARD 
ADDRESS 
 
COMPLAINTS: 
 
HISTORY OF PRESENTING ILLNESS 
DYSPHAGIA                    DURATION 
ODYNOPHAGIA                                             HOARSENESS 
CHEST PAIN                                                    COUGH 
ANOREXIA                                                       DYSPNOEA 
WEIGHT LOSS                                                 HEMOPTYSIS 
REGURGITATION                                          HEMATEMESIS\MALEANA 
OTHERS 
 
PAST HISTORY 
IRRADIATION                                                  DIVERTICULA 
CORROSIVE STRICTURES                           TYLOSIS 
BARRETTS                                                         OTHERS 
P V SYNDROME              
 PERSONAL HISTORY 
MARITAL STATUS                                                  DIET 
SMOKING                                                                  ALCOHOLISM 
OTHERS 
 
FAMILY HISTORY 
 
PHYSICAL EXAMINATION 
PR                                       BP                                            RR 
BUILT                                NUTRITION                          ANEMIA 
JAUNDICE                       LYMPHADENOATHY 
LOCAL EXAMINATION; 
MOUTH AND PHARYND 
NECK 
CHEST 
ABDOMEN 
SPINE & CRANIUM    
  
 
 
INVESTIGATIONS 
URINE                                                                              HEMOGLOBIN 
BLOOD SUGAR                                                              UREA 
                CREATININE                                                  ELECTROLYTES  
 1         ELECTROCARDIOGRAM                                CHEST X RAY 
            ENT OPINION 
            BARIUM SWALLOW 
            ENDOSCOPY 
            BIOPSY 
            USG ABDOMEN 
            CT THORAX & ABDOMEN 
             FNAC OF LYMH NODES 
TREATMENT 
CURATIVE; 
SURGERY 
     TRANS HIATAL ESOPHAGECTOMY 
     COMPLICATIONS  
PALLIATIVE; 
      RADIOTHERAY 
      FEEDING JEJUNOSTOMY 
      STENTING 
SURVIVAL RATE.    
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ME A/S IP.NO ADD C/O HABITS SITE BIOPSY TREAT. COMPLICAT
DASAMY 55\M 804350 ORATHAND D,W,V B,S   L          S            T H E         S, I              
MPATH 45\M 813478 VALLAM D,V,A S,A   M         S            T H E     
PA 45\F 822942 POONDI D,W,A T    L     A    CT  
NIMEGALAI 69\F 825465 TIRUVARUR D,V,A B    M     S    STEN  
TONY 40\M 826515 ARIYALUR W,V,A B,S   L          S             T H E      
AKAMI 40\F 826854 MELATOR D,A,H     M     A             FJ  
VINDAMAL 65\F 828768 PAVAKADU D,V,O T    M     S    RT  
SINATHAN 56\M 828885 MANAMEDU D,O,A B,S    L     A   T H E    E 
 
RADARAJAN 50\M 829292 TRICHY W,V,H T,S,A    M     S    FJ  
ERAN 55\M 830220 KUPAMEDU D,O,A S    M     S    T H E  
RAMANIAN 47\M 835425 KUDAVASAL D,W,A B    M     S     RT  
NGAPPAN 50\M 837040 KUVALYOR D,V,A T    M     S   T H E   H   
RAIRAJ 52\M 837530 TRICHY D,W,A S,A    L    A    T H E     
DAKRISHNAN 59\M 839354 TNJ D,O,A B    L     S    RT      
ANJIUM 65\F 839601 PAPANASAM A T    L    A  T H E  L  
ANMUGAM 50\M 867513 TNJ D,W,A,H T,S    L    A    T H E   I 
VINDARAJ 56\M 867942 KARUR D,W,A T,S,A    M    S     RT  
AMMAL 35\F 868370 IDAYATHI D,V,O,H B    M    S      RT   S 
RUGAN 65\M 860094 TIRUVARUR D,W,O,H T,A    L    S     FJ  
MASAMY 65\M 883014 MANNAI W,V,A,D B,A    M    S   T H E    L,V 
HOORAN 65\M 884448 TIRUKUVALA D,V,H T,S    M    S     RT      
RUGAIYAN 54\M  887445 POONDI D,W,O,H B,S,A    M    S   RT\CT  
NGASAMY 60\M 889965 KUNNAM D,V,A     L    A     FJ  
AGANATHAN 38\M 891895 MANALMEDU W,V,H T,S,A    M    S    T H E  I 
NTHOSAM 56\M 899654 TRICHY D,A T,S    L    S     RT  
LAKAVATHI 40\F 841528 THIRUVAYAR D,W,A B   L     S   T H E  S 
RAMANIAN 47\M 841664 NAGORE D,W, T   L     A   T H E     
NIYAMMAL 50\F 869037 PAPANASAM D,A B   M     A     CT  
RUPPAIAH 60\M 872518 TRICHY D,W    L     S     T H E   L 
MASAMY 65\M 873572 MANNAI D,W,A T   L     S     RT  
NESAN 69\M 874272   PATUKOTAI W,A T   L     S  T H E I 
LAR 36\F 875445 TNJ A B   L    S    RT  
THUSAMY 62\M 876278 DALMIAPET D,W T   M    A STEN  
LAJI 48\M 876702 ARANTHANGI D,W B   L     S   FJ  
VINDARAJ 65\M 877432 KOMBANCHERY A T   L    S  T H E   
AMELU 65\M 8789688 TV MARUDUR D    M    S   FJ   
NGILIMUTHU 60\M 8810288 TNJ A T   L    A  T H E   L,H 
YAPURI 67\M 881719 KEEVALUR D,W,Q B,S,A   M    S  T H E   
THAMMAL 55\F 881849 KUDAVASAL D,A T   L    A    CT  
THALAXMI 45\F 883633 MUTHUPET D,O,A T   L    S  T H E E 
AKIRAMAN 55\M 841943 ORATHANAD V,A B   L    S   STE  
VICHANDRAN 38\M 841943 MANNAI D,W,A  T,S,A M S T H E P 
AGOPAL 62\M 843421 ALIVAIKAL W,A,H B,S L S   RT  
THALAXMI 54\F 846674 KUDANTHAI D,W,O B L A T H E  
ANGARAJ 50\M 847730 NK ROAD  V,A,H T M S T H E  
CKYALASHMI 45\F 854962 TRICHY D,V,O,A  L A T H E P,H 
VARANI 30\F 8575421 PANKANNADU D,W,O B M A T H E  
S.NO NAME A/S IP.NO ADD C/O HABITS SITE BIOPSY
51 PONAMBALAM 62\M 8100461 PONAMBALAM D,W,L S,   M S 
52 AYYAKANNU 50\M 811840 TRICHY D,L S,A U S 
53 VEERAIAN 48\M 813088 PUDUKUDY A S,B L S 
54 SENTHAMARAI 47\M 821127 VALLAM D,V S,T M A 
55 SAROJA 50\F 822351 TNJ D,A S,A L S 
56 MARUDAMUTHU 69\M 823149 JEYANKONDAM L,A B M A 
57 PUNIYAMURTHY 45\M 823391 PATUKOTAI C T U S 
58 MANIYAMMAL 60\F 823391 TV MARUDUR C B L A 
59 MOORTHY 63\M 823698 VELANKANI D,W, T L S 
60 KARUPPAIYA 69\M 826384 BAGORE D,W, A M A 
61 SELVARAJ 40\M 826338 TIRUVARUR A S L S 
62 NATARAJAN 57\M 8826649 TRICHY C A L S 
63 THANGAVEL 69\M 827256 PUDUKOTAI D,L BN L S 
64 NAGARAJAN 57\M 829375 KANDARVAKOT D,L B,T L S 
65 DAKSHINA 60\M 830530 KALAKUDI A,L T M A 
66 KANAKAN 56\M 830535  VETIKADU A,D B L A 
67 JAGANATHAN 64\M 832092 PUDALUR V B M S 
68 MUTHAMMAL 53\M 835621 PILLAYARPET C A U S 
69 SHANTHI  48\F 836128 MUTHUPET C A,T M A 
70 SIVAN 49\M 82746 TRICHY H,L S,B L A 
71 SUGUNTHAN 39\M 871024 VELLAKADU D A M S 
72 RAJAN 65\M 856432 KURUNKULAM D,A T U S 
73 VADIVEL 45\F 836934 MANNAI D.A T L S 
74 KALIYAPERUMAL 50\F 838141 PATIKAD A S L S 
75 OGIR BEEVI 45\F 839656 KATAMPET H T B M S 
76 RATHNAM 60\F 840093 PERAMBALOR D,L B L A 
77 GANESAN 66\M 840216 ARIMANUR L,A S A  L A 
78 MAMURDY 50\M 840375 SETIKADU L,W S U S 
79 SAMINATHAN 60\M 840985 MELATUR D.H S M S 
80 SUBRAMANIAN 47\M 841132 TIRUVARUR L,A S L A 
81 TAMILARASI 50\F 841398 ARIMANUR D,A  L A 
82 SOMASUND 55\M 842403 SIRUKULAM D,L S U S 
83 NATARAJAN 50\M 841910 KANDARVAKO D,A,V A L S 
84 RAJAMANIKAM 45\M 843412 TIRUTHURAI D,L  M S 
85 DURAIRAJ 48\M 844257 MANAMEDU D,.V A L S 
86 MEENAKSHI 69\M 844864 MATIKADU D,V T L S 
87 RAJGOPAL 62\M 846428 MUTHUPET A,C B U A 
88 TAMILSELVI 30\F 846428 PAVADI D,C B M A 
89 RAJ 67\M 883105 PERUMPALLAM C,D A M S 
90 SUGUKUMAR 35\M 866174 KALIKAVAL L A M S 
91 RAKAMAL 67\F 707105 TRICHY D    U NOS 
92 AYYAVU 35\M 861301 MANNAI W C U S 
93 GOMATHY 42\F 816305 NANDANAM  H L S 
94 MEENAL 52\F 8588560 IIRATHANAD W  L A 
95 MURUGAN 55\M 860094 PATALAM D L U S 
96 MUTHAMMAL 69\F 860493 PPATI D A L S 
97 ALAGU DURAI 58\M 860639 TNJ D A U S 
98 KULANDAI 65\M 860798 TRICHY A  U NOS 
99 KALIAMMAL 55\F 870712 PAPANASAM A L U S 
100 SELVARAJ 58\M 870771 VILUKADU W L S A 
 
 
  
 
S.NO NAME A/S IP.NO ADD C/O HABITS SITE BIOPSY 
101 MALAR 49\F 870331 TNJ D T U S 
102 NAGAMMAL 46\F 870445 TRICHY D T U S 
103 SARAVANAN 59\F 875585 PULIKADU A A L S 
104 BALAMMAL 56\F 875689 TRICHY W  L S 
105 JEMILA 49\F 875703 VELLAPURAM W B L A 
106 SAGUNTALA 47\F 879021 TNJ D A M S 
107 RASU 54\M 897827 TRICHY D A M S 
108 NAGAMMAL 59\F 88670 KANDARVA A B L A 
109 JEETA BEEVI 48\F 89876 MELATOR D B M S 
110 NAGAMMAL 60\F 889106 SIRUNGULAM D,W, T U S   
111 FATHIMA 45\F 883603 TRICHY A T L S 
112 MASILAMANI 55/F 88883437 PAPANASAM D,L B L S 
113 NACHIYAR 5/F6 882632 AYYAMPET D,L B L S 
114 RASU 58/M 880679 MARIA.KOVIL D,A,  M S 
115 VAIRAPPU 59/F 872347 NEEDAMANG D B L A 
116 VAIRAM 64/F 825463 TIRUKAVUR A B M S 
117 MANIYAMMAL 69/F 836574 TIRUKAVUR D T M S 
118 PATTAMBAL 58/F 884000 TRICHY A B L A 
119 GANESAN 66/M 844140 TIRUCHITRAM A,D B L A 
120 MEENAKSHI 64/F 846545 VALLAM L  L S 
121 TAMILARASI 56/F 8842993 VURAIYUR D,  U S 
122 SARADAMBAL 55/F 883612 TRICHY A B U S 
123 MARUDAN 34/M 838231 TRICHY S S,A L S 
124 CINNAN 55/M 876451 MANAMED A A L A 
125 KALIYAN 67/M 889432 PATIKADU D S,A L S 
126 MANIAMMAL 78/F 878652 KULATHALAI A T A A 
127 BAGKAM 33/F 878643 MUSIRI  T A A 
128 MURUGAN 66/M 887643 TNJ L  L S 
129 RENGAMAL 65/F 911206 SIRUKAVORD, D, T   
130 DEIVANAI 50/F 909073 POONDI A T   
131 SAMI 62/F 909600 TRICHY A    
132 GNANAMANI 55/F 908788 TNJ A B   
133 MASILAMANI 55/F 889281 NAGAI D B   
134 VASUDEV 50/M 889438 PUDUKUDY D S   
135 MEENAKSHI 69/F 844257 PUDUKOTAI     
136 TAMILSELVI 35/F 846545 TNJ L B   
137 MURUGESH 56/M 887435 TRICHY L A   
138 NAGESH 36/M 88225 MANNAI A S   
139 CHELLAMAL 46/F 908788 PAPANASAM A T   
140 CINDAMANI 58/F 909079 PUNALVASAL D T   
141 NAHOORAN 49/M 884477 KUDAVASAL D    
142 MANOHARAN 68/M 894345 TNJ A    
143 SIVAKUMAR 67/M 882343 TRICHY  S   
144 GEETHA 64/F 898453 NAGAI H A   
145 PREMA 69/F 909454 VELANKANNI A    
146 LATHA 44/F 989091 NAGORE     
147 SUJATHA 66/F 897654 TNJ D  L S 
148 MANJULA 68/F 88765 TRICHY A  U A 
149 MANI 66/M 88765 MUSIRI   L S 
150 RAVI 56/M 88789 VALLAM   L S 
